Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.

Kachnic LA, Winter K, Suntharalingam M, Ilson D, Konski A, Lloyd S, McAvoy SA, Lad T, Olowokure OG, Samson P, Gore EM, Meyer JE, Videtic GMM, Clump DA, Raben A, Kayaleh O, Barker J Jr, Haddock MG, Hopkins JO, Bruner DW

Open source

DOI: 10.1007/s11136-024-03736-7
Published: 2024 Oct
Container: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s11136-024-03736-7,
  title = {Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.},
  author = {Kachnic LA and Winter K and Suntharalingam M and Ilson D and Konski A and Lloyd S and McAvoy SA and Lad T and Olowokure OG and Samson P and Gore EM and Meyer JE and Videtic GMM and Clump DA and Raben A and Kayaleh O and Barker J Jr and Haddock MG and Hopkins JO and Bruner DW},
  year = {2024},
  journal = {Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation},
  doi = {10.1007/s11136-024-03736-7},
  url = {https://doi.org/10.1007/s11136-024-03736-7}
}

RIS

TY  - JOUR
TI  - Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.
AU  - Kachnic LA
AU  - Winter K
AU  - Suntharalingam M
AU  - Ilson D
AU  - Konski A
AU  - Lloyd S
AU  - McAvoy SA
AU  - Lad T
AU  - Olowokure OG
AU  - Samson P
AU  - Gore EM
AU  - Meyer JE
AU  - Videtic GMM
AU  - Clump DA
AU  - Raben A
AU  - Kayaleh O
AU  - Barker J Jr
AU  - Haddock MG
AU  - Hopkins JO
AU  - Bruner DW
PY  - 2024
JO  - Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
DO  - 10.1007/s11136-024-03736-7
UR  - https://doi.org/10.1007/s11136-024-03736-7
ER  -

APA

LA, K., K, W., M, S., D, I., A, K., S, L., SA, M., T, L., OG, O., P, S., EM, G., JE, M., GMM, V., DA, C., A, R., O, K., Jr, B. J., MG, H., JO, H., & DW, B. (2024). Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. https://doi.org/10.1007/s11136-024-03736-7

Source records

pubmed · retrieved 2026-09-25T18:28:53.052Z